1. Introduction {#sec1}
===============

In present medical practice, severe pneumonia with CURB-65 score (confusion, uremia, respiratory rate, low blood pressure, and age 65 years or greater) of ≧ 3 points comprised more than 16% and 25% of 30-day mortality rate among community-acquired pneumonia (CAP) and healthcare-associated pneumonia (HCAP), respectively \[[@B1]\]. Initial broad-spectrum empiric antibiotic selection is important because inadequate or delayed antibiotic treatment results in high mortality. However, overuse of empirical broad-spectrum antibiotics can create multidrug-resistant (MDR) pathogens and contribute to antibiotic-induced complications.

Selection of antibiotics for initial empirical therapy is based on prediction of the most likely pathogens and knowledge of local susceptibility. Guidelines provide some risk factors for specific pathogens \[[@B2], [@B3]\]. This can help us decide initial empiric antibiotics. In general, physicians prescribe initial antibiotics which should be effective for*Pseudomonas aeruginosa*(*P. aeruginosa*) and MDR pathogens in patients combining HCAP and hospital-acquired pneumonia (HAP) with severe sepsis. If*Staphylococcus aureus*(*S. aureus*) is considered, vancomycin, linezolid, or teicoplanin is added due to high risk of methicillin-resistant*S. aureus* (MRSA). The Infectious Diseases Society of America and American Thoracic Society suggest risk factors of*S. aureus* pneumonia in patients with hemodialysis, lung abscess, structure lung disease, injection drug use, prior influenza, prior antibiotic therapy, and endobronchial obstruction \[[@B2]\].

However, the best indicator of*S. aureus* infection is that Gram staining shows a single/predominant Gram-positive coccus with clustered and polymorphonuclear cells. Then,*S. aureus* infection could be confirmed by following culture report. But culture report needs 3-4 days. Patients with late-onset HAP and HCAP are at greater risk for infection with MDR pathogens \[[@B3]\]. Thus, it becomes an important issue whether critically ill patients with severe HAP and HCAP have probability of*S. aureus* infection in present clinical practice.

We designed a prospective observational study to determine the prevalence and epidemiologic risk factor of*S. aureus* infection among patients admitted to intensive care unit (ICU) due to severe HCAP and HAP.

2. Materials and Methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

From July 2007 to June 2010, patients who were admitted to the ICU at Chang Gung Memorial Hospital, Keelung, due to HCAP and HAP with severe sepsis or septic shock were enrolled in this study. The ICU is a medical and closed unit in our hospital. This study was approved by the Institutional Review Board at Chang Gung Memorial Hospital (96-0132B, 97-0121C, and 98-1682C). The following patient data were recorded within the first 3 days after admission: age; gender; medical history; lower respiratory tract sample for semiquantitative culture; Acute Physiology and Chronic Health Evaluation (APACHE) II score; and adverse events. History of intravenous drug use and prior antibiotic use within 30 days was recorded according to the statement of patient or patient\'s family. Endotracheal aspirates were used as lower respiratory tract samples for culture initially. If cultures were negative, bronchoalveolar lavages were performed to detect pathogens. Samples contaminated by upper airway secretions, as reflected by more than 10 squamous epithelial cells/low power field, were excluded.

2.2. Disease Definitions {#sec2.2}
------------------------

Pneumonia was defined as new abnormal infiltration on chest radiograph with respiratory symptoms or fever. Pneumonia was classified as HCAP and HAP according to guidelines \[[@B3]\]. HCAP includes any patient who was hospitalized in an acute care hospital for two or more days within 90 days of the infection; resided in a nursing home or long-term care facility; received recent intravenous antibiotic therapy, chemotherapy, or wound care within the past 30 days of the current infection; or attended a hospital or hemodialysis clinic. HAP is defined as pneumonia that occurs 48 hours or more after admission, which was not incubating at the time of admission. Severe sepsis and septic shock were defined according to the criteria established in the Consensus Conference \[[@B4]\]. Systemic inflammatory response syndrome (SIRS) was defined as fulfillment of two or more of the following criteria: (1) body temperature \>38°C or \<36°C; (2) respiratory rate \>24 breaths/minute; (3) heart rate \>90 beats/minute; and (4) white blood count \>12,000/*μ*L or \<4000/*μ*L or \>10% bands. Sepsis was defined as SIRS according to a confirmed or suspected microbial etiology. Severe sepsis was defined as sepsis with one or more dysfunctional organs or hypotension. Septic shock was defined as sepsis with hypotension unresponsive to fluid resuscitation, which further required vasopressors to maintain blood pressure during the first three days following ICU admission. Acute renal failure was diagnosed as a rapidly rising serum creatine level ≥0.5 mg/dL over the baseline value \[[@B5]\]. Disease severity was assessed with the APACHE II score \[[@B6]\]. Survivors were defined as patients who were alive 30 days after ICU admission.

2.3. Treatment {#sec2.3}
--------------

Standard bundle therapies, including fluid resuscitation, broad-spectrum antibiotics, drainage, blood transfusion, sedation/paralysis, blood glucose control, hemodialysis, stress ulcer prophylaxis, and basic support, were provided to all patients according to the recommended guidelines \[[@B7]\]. Initial broad-spectrum antibiotics were chosen by the Taiwan Guidelines for Pneumonia Management (2007 version) or Guidelines of American Thoracic Society \[[@B3]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

Statistical analysis was performed with the Statistical Package for the Social Sciences (SPSS) V17.0 for Windows (SPSS, Inc., Illinois, USA). Differences for the continuous variables between the two groups were analyzed by Mann-Whitney test. Differences for categorical variables between the two groups were compared by Pearson chi-square test or Fisher\'s exact test. General linear model was used to determine the associations of*S. aureus* pneumonia among all factors. A *p* value of less than 0.05 was considered statistically significant. Odds ratio is the odds that a patient is exposed to the risk factor divided by the odds that a control is exposed to.

3. Results {#sec3}
==========

During the study period, 493 patients with severe sepsis or septic shock were screened ([Figure 1](#fig1){ref-type="fig"}). A total of 282 patients were enrolled for analysis, and 211 patients were excluded. The reasons for exclusion included nonpneumonia infection (*n* = 73), coisolated pathogens (*n* = 51), and no detectable pathogens (*n* = 87) in lower respiratory tract sample for culture. Patients with coisolated pathogens and no detectable pathogens were excluded to reduce the possible bias maximally due to concerns of pathogen colonization and unknown pathogens. No patients withdrew. Initially, 152 and 130 patients received adequate and inadequate antibiotic therapy, respectively. Fifty-nine and 66 patients died in adequate and inadequate antibiotic groups, respectively. Clinical characteristics of HCAP or HAP patients with severe sepsis are shown in [Table 1](#tab1){ref-type="table"}. Patients with*S. aureus* pneumonia had higher percentage of liver cirrhosis and diabetes mellitus history. Percentages of history of chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), hypertension, and hemodialysis were similar between presence and absence of*S. aureus* pneumonia. There were no differences in age, APACHE II score, sex, adverse events, and 30-day mortality rates between patients with and without*S. aureus* infection.

[Table 2](#tab2){ref-type="table"} shows the isolated pathogens with initial adequate or inadequate antibiotic treatment. The most frequently isolated pathogens, in decreasing order, were*P. aeruginosa*,*S. aureus*,*Acinetobacter baumannii*,*Klebsiella pneumoniae*(*K. pneumoniae*),*Escherichia coli* and so forth. All patients with*Streptococcus pneumonia* (*S. pneumonia*) infection were prescribed adequate antibiotic treatment initially. Only*S. pneumonia* infection was associated with 30-day mortality ([Table 3](#tab3){ref-type="table"}). Patients with*S. pneumonia* infection had higher survivor rate. There was no difference in mortality between other pathogens and mortality.

After regression analysis, patient\'s history of CHF, liver cirrhosis, and diabetes mellitus were independent factors associated with*S. aureus* pneumonia ([Table 4](#tab4){ref-type="table"}). The odds ratios of CHF, liver cirrhosis, and diabetes mellitus were 2.242, 3.098, and 1.899, respectively. The*S. aureus* pneumonia was not correlated with history of prior antibiotic use, COPD, hypertension, and chronic renal failure. The*S. aureus* pneumonia was also not associated with age, gender, APACHE II score, adverse events, and mortality.

4. Discussion {#sec4}
=============

The present investigation is the first to find that history of CHF, liver cirrhosis, and diabetes mellitus increased the risk of*S. aureus* infection in patients with severe HAP or HCAP. Immunodeficiency in cirrhosis is multifactorial and might not be reversed by interventions. Polymorphonuclear leukocyte dysfunction and complement deficiency are well known as main causes leading to infection predisposition \[[@B8]\].*S. aureus* has been reported to be the most frequently (27.4%) isolated pathogen from blood and ascites fluid in patients with liver cirrhosis \[[@B9]\]. From the database of a surveillance study of*S. aureus* infections, bacteremia and bone infection were more frequent in the chronic liver disease group when compared with the other-disease group \[[@B10]\]. After multivariate analysis, chronic liver disease was a factor significantly associated with 30-day mortality. However, there was no difference in pneumonia rate between the chronic liver disease and other-disease groups. This was dissimilar from the current study\'s findings. In this research, we found that HCAP or HAP patients with liver cirrhosis had higher percentage of*S. aureus* infection. More studies may be needed to clarify the association between*S. aureus* pneumonia and liver cirrhosis.

Compared with nondiabetes patients with severe pneumonia, diabetes patients had 1.899 of odds ratio for*S. aureus* infection in this study. Hyperglycemia promoted respiratory*S. aureus* infection, and metformin modified glucose flux across the airway epithelium to limit hyperglycemia-induced bacterial growth \[[@B11]\]. Shorr et al. developed a risk score to identify*S. aureus* in patients with HCAP \[[@B12]\]. Female with diabetes was one of eight variables in the final risk score. Furthermore, diabetes could be thought of as immunosuppressive disease, a risk factor of methicillin-resistant*S. aureus* infection (MRSA) \[[@B14]\]. However, in a study of healthcare-associated infection, Erben et al. found that diabetes mellitus was not a risk factor for*S. aureus* pneumonia \[[@B13]\]. Diabetes mellitus was a risk factor for*S. aureus* infection at surgical site. More studies may be necessary to determine the relationship between*S. aureus* pneumonia and diabetes mellitus.

In this work,*S. aureus*infection was the second most frequently found pathogen in patients with severe pneumonia. In Korea and Japan, the frequent pathogens in HCAP, in decreased order, were*S. pneumonia*,*S. aureus*,*P. aeruginosa*, and*K. pneumoniae* \[[@B15], [@B16]\]. Also,*S. pneumonia*,*P. aeruginosa*, and*S. aureus* were the frequently detected pathogens in HCAP in Spanish \[[@B17]\].

In this study, patients with chronic obstructive pulmonary disease (COPD) did not have higher risk of*S. aureus* infection or colonization. That is similar to Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults \[[@B2]\]. However, in a retrospective chart review study, the risk for MRSA was increased by tobacco use (OR = 2.31, CI 1.23--4.31) and COPD (OR = 3.76, CI 1.74--8.08) in CAP patients \[[@B18]\], and the risk of COPD disappeared in HAP patients. Thus, whether COPD increases risk for*S. aureus* in HCAP is still unclear. About the history of CHF, we did not find published reports or studies showing the presence of correlation between CHF and*S. aureus*. Hemodialysis was not associated with*S. aureus* pneumonia in this work. This may be due to the fact that more than 90% identified*S. aureus* events were bloodstream infection \[[@B19]\]. Although hemodialysis did not significantly increase the risk of*S. aureus* pneumonia, patients with end-stage renal disease and hemodialysis patients had increased risk of*S. aureus* bacteremia \[[@B20]\].

As we know, inadequate empiric antimicrobial treatment may be associated with excess hospital mortality in pneumonia \[[@B3]\]. However, this point might not be constant after bundle therapy of severe sepsis. In our previous study, there was no difference in mortality between initial adequate and inadequate antibiotic therapy in patients with severe sepsis \[[@B21]\]. In this work, even though most of patients were prescribed initial adequate antibiotic therapy for*P. aeruginosa* and*K. pneumoniae*, their mortality rates did not decrease significantly. Only patients with*S. pneumonia* infection had significantly higher survival rate. The most likely reason might be that all patients with*S. pneumonia* infection were prescribed adequate empiric antibiotic therapy.

There are two limitations in this study. First, the accuracy of diagnosing pathogens is based on lower respiratory tract quantitative cultures of endotracheal aspirates, protected specimen brush, or bronchoalveolar lavage samples. The lower respiratory tract culture in our hospital is semiquantitative. Further, a positive culture cannot always distinguish a pathogen from a colonizing organism \[[@B3]\]. The culture results in this work may include colonizing pathogens. Second, there is a possible bias in statistical analysis. The percentage of history of CHF was low in this study. That made the statistical power low in regression analysis.

In conclusion, the traditional risk factors for*S. aureus* infection may change or vary. This study concludes that liver cirrhosis and diabetes mellitus may be risk factors for*S. aureus* infection in patients with HCAP or HAP. Using these features may allow us to select adequate empiric antibiotics.
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###### 

Clinical characteristics between presence and absence of *S. aureus* infection in HCAP or HAP patients with severe sepsis.

                                 *S. aureus* (*N* = 63)   No *S. aureus* (*N* = 219)   *p* value
  ------------------------------ ------------------------ ---------------------------- -----------
  Age, years^*∗*^                73.7 ± 14.4              73.9 ± 13.0                  0.938
  APACHE II score^*∗*^           26.0 ± 6.7               27.0 ± 7.8                   0.477
  Sex, number (%)                                                                      0.916
   Male                          43 (68.3)                151 (68.9)                    
   Female                        20 (31.7)                68 (31.1)                     
  History, number (%)                                                                   
   Prior antibiotic use          20 (31.7)                64 (29.2)                    0.700
   Intravenous drug use          0 (0.0)                  0 (0.0)                      †
   COPD                          9 (14.3)                 47 (21.5)                    0.208
   CHF                           10 (15.9)                17 (7.8)                     0.054
   Hypertension                  26 (41.3)                90 (41.1)                    0.980
   Liver cirrhosis               11 (17.5)                14 (6.4)                     0.006
   Hemodialysis                  4 (6.3)                  20 (9.1)                     0.485
   Diabetes mellitus             27 (42.9)                62 (28.3)                    0.029
  Adverse events, number (%)                                                            
   RF with intubation and MV     63 (100.0)               219 (100.0)                  †
   GI bleeding                   8 (12.7)                 33 (15.1)                    0.638
   Shock                         31 (49.2)                100 (45.7)                   0.619
   New arrhythmia                4 (6.3)                  13 (5.9)                     1.000
   Acute renal failure           27 (42.9)                92 (42.0)                    0.904
   Jaundice                      7 (11.1)                 17 (7.8)                     0.401
   Thrombocytopenia              23 (36.5)                83 (37.9)                    0.841
  30-day mortality, number (%)   25 (39.7)                100 (45.7)                   0.400

*S. aureus*: *Staphylococcus aureus*; HCAP: healthcare-associated pneumonia; HAP: hospital-acquired pneumonia; APACHE: Acute Physiology and Chronic Health Evaluation; COPD: chronic obstructive pulmonary disease; CHF: congestive heart failure; RF: respiratory failure; MV: mechanic ventilator; and GI: gastrointestinal

^*∗*^Data is shown as mean ± standard deviation.

^†^No statistic was computed because variable is a constant.

###### 

Pathogens in severe pneumonia between adequate and inadequate antibiotic use.

  ---------------------------------------------------------------------------------------------
  Pathogens                        Adequate\          Inadequate\        Total\
                                   *N* (% of total)   *N* (% of total)   *N* (% of pathogens)
  -------------------------------- ------------------ ------------------ ----------------------
  *Pseudomonas aeruginosa*         53 (74.6)          18 (25.4)          71 (25.1)

  *Staphylococcus aureus*          31 (49.2)          32 (50.8)          63 (22.3)

   MSSA                            10 (15.9)          3 (4.8)            13 (4.6)

   MRSA                            21 (33.3)          29 (46.0)          50 (17.7)

  *Acinetobacter baumannii*        18 (35.3)          33 (64.7)          51 (18.0)

  *Klebsiella pneumoniae*          32 (72.7)          12 (27.3)          44 (15.5)

  *Escherichia coli*               21 (67.7)          10 (32.3)          31 (11.0)

  *Streptococcus pneumonia*        11 (100.0)         0 (0.0)            11 (3.8)

  *Stenotrophomonas maltophilia*   3 (42.9)           4 (57.1)           7 (2.5)

  *Enterobacter*                   3 (60.0)           2 (40.0)           5 (1.8)
  ---------------------------------------------------------------------------------------------

MSSA: Methicillin-Sensitive *Staphylococcus aureus*; MRSA: Methicillin-Resistant *Staphylococcus aureus*.

###### 

Difference in mortality among pathogens in severe pneumonia.

  Pathogens                        Survivors   Nonsurvivors   *p* value
  -------------------------------- ----------- -------------- -----------
  *Pseudomonas aeruginosa*                                    0.338
   Yes                             34          28              
   No                              114         97              
  *Staphylococcus aureus*                                     0.400
   Yes                             38          25              
   No                              119         100             
  *Acinetobacter baumannii*                                   0.617
   Yes                             30          21              
   No                              127         104             
  *Klebsiella pneumoniae*                                     0.868
   Yes                             25          19              
   No                              132         106             
  *Escherichia coli*                                          0.776
   Yes                             18          13              
   No                              139         112             
  *Streptococcus pneumonia*                                   0.026
   Yes                             10          1               
   No                              147         124             
  *Stenotrophomonas maltophilia*                              0.137
   Yes                             6           1               
   No                              151         124             
  *Enterobacter*                                              0.658
   Yes                             2           3               
   No                              155         122             

###### 

General linear model to predict *Staphylococcus aureus* pneumonia.

  Variables                 *B*      *p* value   95% confidence interval   
  ------------------------- -------- ----------- ------------------------- -------
  Age, years                0.000    0.839       −0.004                    0.004
  APACHE II score           −0.005   0.218       −0.012                    0.003
  Sex, male                 −0.014   0.810       −0.124                    0.097
  History                                                                   
   Prior antibiotic use     −0.010   0.859       −0.119                    0.099
   COPD                     −0.053   0.434       −0.185                    0.080
   CHF                      0.175    0.043       0.006                     0.345
   Hypertension             −0.026   0.639       −0.135                    0.083
   Liver cirrhosis          0.334    0.003       0.117                     0.552
   Hemodialysis             −0.080   0.398       −0.267                    0.107
   Diabetes mellitus        0.113    0.049       0.001                     0.225
  Adverse events                                                            
   GI bleeding              −0.076   0.317       −0.224                    0.073
   Shock                    0.060    0.304       −0.054                    0.173
   New arrhythmia           0.006    0.957       −0.205                    0.216
   Acute renal failure      −0.012   0.831       −0.121                    0.097
   Jaundice                 −0.097   0.392       −0.319                    0.125
   Thrombocytopenia         0.000    0.989       −0.111                    0.110
  30-day mortality, death   −0.023   0.692       −0.136                    0.090
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